Abstract: PO0711
SARS-CoV-2 Infection and Outcomes in Chronic Dialysis Patients
Session Information
- COVID-19: Dialysis Patients
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Lacson, Eduardo K., Dialysis Clinic Inc, Nashville, Tennessee, United States
- Aweh, Gideon N., Dialysis Clinic Inc, Nashville, Tennessee, United States
- Ladik, Vladimir, Dialysis Clinic Inc, Nashville, Tennessee, United States
- Manley, Harold J., Dialysis Clinic Inc, Nashville, Tennessee, United States
- Stewart, Carol, Dialysis Clinic Inc, Nashville, Tennessee, United States
- Johnson, Doug, Dialysis Clinic Inc, Nashville, Tennessee, United States
Background
The SARS-COV-2 pandemic (COVID) impacted ESRD patients on dialysis, categorized by the CDC as immunocompromised. We describe the characteristics and outcomes in patients treated by a non-profit dialysis provider.
Methods
From 2/17 to 5/29, 2020, Dialysis Clinic Inc. had identified 422 COVID+ patients from 90 clinics in 20 states. We compared their characteristics relative to the uninfected source clinic population (N=6,993) and tracked outcomes over the 15-week period.
Results
Comparative characteristics are shown in the table (*p<0.05). Hospitalization occurred in 295 (70%) with 75 deaths, 159 discharges and 61 still hospitalized. Ten patients died <30 days post-discharge. Another 11 deaths occurred in 116 non-hospitalized patients. Overall, 96 of 422 died (22.7%). While more black patients were infected, death rates were higher in white than black dialysis patients (31.5% vs. 18.8%, p=0.008).
Conclusion
Chronic dialysis patients with COVID have higher death rates than the general population. Infected patients tended to be older, with more comorbidity, particularly DM/CVD, and utilized respiratory inhalers/assistance. Group home residents were overrepresented with COVID while home dialysis patients were disproportionately spared.
| Source: 90 DCI Clinics w/ 7,415 patients | COVID+ | Non-COVID |
| N of Patients (%) | 422 (5.7%) | 6,993 (94.3%) |
| Age (years) | 65.3±13.3* | 62.1±14.9 |
| % Male | 60.2 | 57.3 |
| % White | 26.3* | 36.0 |
| % Black | 56.9* | 46.5 |
| % Other Race | 16.8 | 17.5 |
| Vintage (days) | 1,692 ± 1,699 | 1,668 ± 1,808 |
| % Home Dialysis | 3.3* | 14.9 |
| % CVC | 25.6 | 22.0 |
| % Group Home | 38.9* | 6.4 |
| % Albumin <3.5 g/dL | 19.2* | 14.5 |
| # Comorbid Dis. | 3.3±1.9* | 3.0±1.9 |
| % DM | 69.7* | 57.7 |
| % AHD | 26.5* | 21.7 |
| % CVA | 11.8* | 8.5 |
| % HTN | 77.7* | 81.7 |
| % Inhaler Use | 28.2* | 19.9 |
| % Wheelchair | 3.6* | 1.8 |
| % ADL Help | 0.9* | 0.3 |
| BMI | 29.1 ± 7.4 | 28.8 ± 8.9 |
Note: % CHF, COPD, PVD, Smoking, ACEi-ARBs, Steroids, Flu/Pneumonia Vaccines similar.